Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1322"
Predicate | Value (sorted: default) |
---|---|
rdfs:label | |
rdf:type | |
?:Evidence_enzyme_system | |
?:Evidence_numb_subjects | |
?:Evidence_object_dose | |
?:Evidence_precip_dose | |
?:Evidence_type | |
?:Evidence_value | |
?:content |
"Route of administration: oral
study duration: 10 days pre-treatment with erythromycin 400mg 3x/day
population: 12 healthy adults
male: 12
female: 0
ages: 25-41 years
AUC_i/AUC: 322/200 ng*hr/ml
NOTE: The 0-48 hout AUC values were used rather than the 0-infinity values
Quote:
Twelve healthy male volunteers were randomly allocated to one of the two different treatment sequences, placebo-erythromycin or erythromycin-placebo, with an at least 6-week washout period between the two trial phases. Each volunteer received 400 mg erythromycin or matched placebo given orally three times a day for 10 days and an oral dose (0.8 mg) of alprazolam on the posttreatment day 8. Plasma concentration of alprazolam was measured up to 48 hours after the administration, and psychomotor function was assessed at each time of blood samplings with use of the Digit Symbol Substitution Test, visual analog scale, and Udvalg for kliniske unders�er side effect rating scale. RESULTS: Erythromycin significantly (p < 0.001) increased the area under the plasma concentration-time curves (200 +/- 43 versus 322 +/- 49 ng . hr/ml from 0 to 48 hours and 229 +/- 52 versus 566 +/- 161 ng . hr/ml from 0 hour to infinity), decreased the apparent oral clearance (1.02 +/- 0.31 versus 0.41 +/- 0.12 ml/min/kg), and prolonged the elimination half-life (16.0 +/- 4.5 versus 40.3 +/- 14.4 hours) of alprazolam. However, any psychomotor function variables did not differ significantly between the erythromycin and placebo trial phases."
|
dc:creator | |
dc:date |
"06/25/2007 13:07:07"
|
rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ erythromycin_increases_auc_alprazolam, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1202 }